<DOC>
	<DOCNO>NCT01094548</DOCNO>
	<brief_summary>Tecemotide ( L-BLP25 ) believe induce Mucinous glycoprotein 1 ( MUC1 ) -specific T-cell response vaccination . The primary purpose study ascertain whether vaccination tecemotide ( L-BLP25 ) induce MUC1-specific T-cell response slowly progressive chemotherapy naive multiple myeloma subject .</brief_summary>
	<brief_title>Study Tecemotide ( L-BLP25 ) Subjects With Slowly Progressive Multiple Myeloma With Symptoms Who Have Had Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Documented previously untreated , Mucinous glycoprotein 1 ( MUC1 ) expressing , slowly progressive asymptomatic multiple myeloma increase Mprotein concentration display two occasion separate interval least 4 week within last 18 month , Documented MUC1expressing stage II III multiple myeloma treatmentfree interval least 3 month follow prior antitumor therapy , fulfil criterion stable response/plateau phase Signed write informed consent MUC1expressing myeloma cell bone marrow Greater equal ( &gt; = ) 18 year age Life expectancy least 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status less equal ( &lt; = ) 1 study entry Effective contraception male female subject , possibility conception exist A platelet count &gt; =100 x 10^9/Liter , white blood cell &gt; =2.5 x 10^9/Liter , hemoglobin &gt; =90 gram per liter ( g/L ) Total bilirubin &lt; = 1.5 x upper reference range Aspartate aminotransferase ( AST ) &lt; = 2.5 x upper reference range Serum creatinine &lt; = 2 x upper reference PreTherapies : Previous exposure MUC1 target therapy Radiotherapy investigational drug 30 day start treatment study Receipt immunotherapy ( Example : interferon , tumor necrosis factor [ TNF ] , interleukins , biological response modifier [ granulocyte macrophage colony stimulate factor { GMCSF } , granulocyte colony stimulate factor { GCSF } , macrophagecolony stimulate factor { MCSF } ] , monoclonal antibody ) within 4 week ( 28 day ) prior randomization Any preexist medical condition require chronic oral intravenous steroid immunosuppressive therapy except maintenance dos prednisone &lt; =10 milligram per day ( mg/day ) Medical Conditions : Autoimmune disease opinion investigator could compromise safety subject study Hereditary congenital immunodeficiency Known hypersensitivity reaction component study treatment Clinically significant cardiac disease , Example : New York Heart Association ( NYHA ) class IIIIV ; unstable angina , uncontrolled arrhythmia uncontrolled hypertension , myocardial infarction previous 6 month Other previous malignancy within 5 year , exception history previous basal cell carcinoma skin , carcinoma situ uterine cervix , gastrointestinal intramucosal carcinoma Known Hepatitis B and/or C Splenectomy Standard Safety : Known alcohol drug abuse Medical psychological condition would permit subject complete study sign inform consent Significant disease , investigator 's opinion , would exclude subject study Pregnant breastfeed woman , woman childbearing potential , unless use effective contraception determine investigator . Subjects investigator considers may risk pregnancy pregnancy test perform per institutional standard Participation another clinical study within past 30 day Legal incapacity limit legal capacity Concurrent treatment nonpermitted drug Any reason , opinion investigator , precludes subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>L-BLP25 liposome</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>